Related references
Note: Only part of the references are listed.Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4)
Hugues Melliez et al.
CLINICAL INFECTIOUS DISEASES (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Martin Martinot et al.
EMERGING INFECTIOUS DISEASES (2018)
Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
Martin Rao et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Immune checkpoint inhibitor therapy A double-edged sword?
Ho Jin Kim et al.
NEUROLOGY (2017)
Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review
Elizabeth C. Neil et al.
BLOOD ADVANCES (2017)
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Preclinical Disease Activity in Multiple Sclerosis: A Prospective Study of Cognitive Performance prior to First Symptom
Marianna Cortese et al.
ANNALS OF NEUROLOGY (2016)
Progressive multifocal leukoencephalopathy therapy
David B. Clifford
JOURNAL OF NEUROVIROLOGY (2015)
Increased Program Cell Death-1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy
Chen Sabrina Tan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Progressive Multifocal Leukoencephalopathy in Transplant Recipients
Farrah J. Mateen et al.
ANNALS OF NEUROLOGY (2011)